4.7 Article

Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America

期刊

CLINICAL INFECTIOUS DISEASES
卷 54, 期 7, 页码 1026-1034

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir1012

关键词

-

资金

  1. National Institutes of Health (General Clinical Research Centers [GCRC]) [U01-AI069918, U01-AA013566, U01-AI-35042, U01-AI-35043, U01-AI-35039, 5-M01-RR-00052, U01-AI-35040, U01-AI-35041, U01-AI38855]
  2. AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) [U01-AI38858, U01-AI68634, U01-AI68636, AI-69432, AI-69434, U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, U01-AI-42590, U01-HD-32632, UL1-RR024131, P30-AI27757, K23-AI-61-0320, P30-AI27767, P30-AI50410, RR025747, P30-AI54999, R01-DA04334, R01-DA12568, R01-MH54907, R24-AI067039, N02-CP55504, Z01 CP010176, AHQ290-01-0012, K01-AI071754, K24-00432, R01-DA11602, K01-AI071725, R01 AG026250, P30 AI027763]
  3. Canadian Institutes for Health Research (CIHR) [TGF-96118, HCP-97105, CBR-86906, CBR-94036, KRS-86251, 169621]
  4. Canadian Trials Network [242]
  5. Centers for Disease Control [CDC200-2006-18797]
  6. Pfizer
  7. Merck
  8. Abbott
  9. Gilead
  10. Tibotec
  11. Bristol-Myers Squibb
  12. GlaxoSmithKline
  13. Schering Plough Canada

向作者/读者索取更多资源

Background. Anal cancer is one of the most common cancers affecting individuals infected with human immunodeficiency virus (HIV), although few have evaluated rates separately for men who have sex with men (MSM), other men, and women. There are also conflicting data regarding calendar trends. Methods. In a study involving 13 cohorts from North America with follow-up between 1996 and 2007, we compared anal cancer incidence rates among 34 189 HIV-infected (55% MSM, 19% other men, 26% women) and 114 260 HIV-uninfected individuals (90% men). Results. Among men, the unadjusted anal cancer incidence rates per 100 000 person-years were 131 for HIV-infected MSM, 46 for other HIV-infected men, and 2 for HIV-uninfected men, corresponding to demographically adjusted rate ratios (RRs) of 80.3 (95% confidence interval [CI], 42.7-151.1) for HIV-infected MSM and 26.7 ( 95% CI, 11.5-61.7) for other HIV-infected men compared with HIV-uninfected men. HIV-infected women had an anal cancer rate of 30/100 000 person-years, and no cases were observed for HIV-uninfected women. In a multivariable Poisson regression model, among HIV-infected individuals, the risk was higher for MSM compared with other men (RR, 3.3; 95% CI, 1.8-6.0), but no difference was observed comparing women with other men ( RR, 1.0; 95% CI, 0.5-2.2). In comparison with the period 2000-2003, HIV-infected individuals had an adjusted RR of 0.5 (95% CI,.3-.9) in 1996-1999 and 0.9 (95% CI,.6-1.2) in 2004-2007. Conclusions. Anal cancer rates were substantially higher for HIV-infected MSM, other men, and women compared with HIV-uninfected individuals, suggesting a need for universal prevention efforts. Rates increased after the early antiretroviral therapy era and then plateaued.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据